<DOC>
	<DOCNO>NCT01219400</DOCNO>
	<brief_summary>The purpose study explore whether novel therapy type 2 diabetes , vildagliptin , inhibit dipeptidyl peptidase-4 ( DPP-4 ) , affect glucagon counterregulation hypoglycemia insulin-treated patient type 2 diabetes . Vildagliptin give , together on-going insulin therapy , one month , whereafter hypoglycemia induce standardized condition , glucagon response determine , compare month placebo treatment .</brief_summary>
	<brief_title>Vildagliptin Glucagon Response Hypoglycemia Insulin-Treated Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Vildagliptin inhibitor dipeptidyl peptidase-4 ( DPP-4 ) inhibit glucagon secretion stimulates insulin secretion . This improve glycemia subject type 2 diabetes low risk hypoglycemia . If hypoglycemia nevertheless develop , important vildagliptin condition inhibit glucagon secretion , since would aggravate hypoglycemia . It indeed previously demonstrate type 2 diabetes vildagliptin dos inhibit glucagon secretion hypoglycemia . This study explore whether vildagliptin affect glucagon counterregulation hypoglycemia insulin-treated patient type 2 diabetes . Vildagliptin give , together on-going insulin therapy , one month , whereafter hypoglycemia induce standardized condition , glucagon response determine , compare month placebo treatment . The hypoglycemia induce bvy standardized clamp procedure .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Type 2 diabetes Insulin treatment Age &gt; 18 year HbA1c &lt; =8.5 % Pregnancy Lactation Acute infection Liver disease Treatment cortisol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>DPP-4</keyword>
	<keyword>GLP-1</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Catecholamines</keyword>
	<keyword>Counterregulation</keyword>
	<keyword>Insulin-treatment</keyword>
	<keyword>Type 2 diabetes</keyword>
</DOC>